SCHEMBL20178633

SCHEMBL20178633

CN1Cc2cc(F)c(C(F)(F)F)cc2C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
NR1H2 P55055 1/20 0.34
AR P10275 6/20 0.33
SIRT6 Q8N6T7 1/20 0.33
KDM1A O60341 1/20 0.33
GPR3 P46089 1/20 0.32
KIF11 P52732 3/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
SLC6A4 P31645 1/20 0.32
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178632 0.80 HTR2A (0.38) HTR2AHTR2CHTR2BARKDM1A
SCHEMBL20173787 0.79 HTR2A (0.44) HTR2AHTR2CHTR2BARKDM1A
SCHEMBL20178676 0.77 HTR2A (0.43) HTR2AHTR2CHTR2BKIF11
SCHEMBL25946962 0.73 MAOA (0.49) MAOAMAOBSLC6A4
SCHEMBL23745350 0.71 KDM1A (0.35) KDM1AMAOAMAOBSLC6A4
SCHEMBL8262221 0.71 AR (0.37) HTR2AHTR2CHTR2BARKDM1A
SCHEMBL3874950 0.71 ALDH1A1 (0.36) HTR2AHTR2CHTR2BARKDM1A
SCHEMBL15850523 0.69 KIF11 (0.44) ARKDM1AGPR3KIF11POLB
SCHEMBL12706078 0.69 MAOA (0.44) MAOAMAOBSLC6A4
SCHEMBL18256756 0.69 MAOA (0.49) MAOAMAOBSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.